VANESSA TUCKER: Open Payments
NPI 1861551400 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$762 in 42 payments from 13 companies in 2025. Trend: 2023 $1,044 · 2024 $1,296 · 2025 $762
Food & beverage: $762
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $183 |
| ABBVIE INC. | 17 | $180 |
| Axsome Therapeutics, Inc. | 4 | $129 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $17 |
| ACADIA Pharmaceuticals Inc | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: INGREZZA, VRAYLAR, Auvelity, FANAPT, CAPLYTA, GIVLAARI, GEMTESA, ZURZUVAE.
Industry payments across KY — which companies pay providers there.
